Scholars@Duke
Corinne Mary Linardic

Corinne Mary Linardic

Associate Professor of Pediatrics
Pediatrics, Hematology-Oncology
linar001@mc.duke.edu
Box 102382, DUMC, Durham, NC 27710
LSRC Bldg Rm B361F, Research Drive, Durham, NC 27710

Scholarly Works - Conferences

Abstract 1155: High-throughput screening identifies synergistic drug interactions between CDK8/19 and DHFR inhibitors in rhabdomyosarcoma

Conference Cancer Research · April 3, 2026 AbstractRhabdomyosarcoma (RMS) is an aggressive pediatric soft-tissue sarcoma marked by substantial treatment-related morbidity and poor outcomes, particularly in metastatic or recurrent disease. Although ... Full text Cite

Abstract 2758: PAX3/7::FOXO1 fusion detection and transcriptomic prediction from whole-slide images of rhabdomyosarcoma using attention-based deep learning frameworks: A multi-institutional study.

Conference Cancer Research · April 3, 2026 AbstractBackground:Rhabdomyosarcoma (RMS) is a highly malignant pediatric soft-tissue sarcoma where molecular subtyping, partic ... Full text Cite

Abstract A022-PR005: CDK8 Inhibition Releases the Muscle Differentiation Block in Fusion-Driven Alveolar Rhabdomyosarcoma

Conference Cancer Research · September 25, 2025 AbstractFunctional and chemical genomic approaches, such as the Broad Institute’s Cancer Dependency Map and PRISM (Profiling Relative Inhibition S ... Full text Cite

Integrated molecular characterization of pediatric soft tissue sarcomas: A report from the COG and CCDI molecular characterization initiative.

Conference Journal of Clinical Oncology · June 2025 10025Background: The Molecular Characterization Initiative (MCI), a partnership between the Children’s Oncology Group (COG) a ... Full text Cite

Abstract 6707: Direct in vivo CRISPR screen identifies BAP1 and FAT1 as potent tumor suppressors in sarcomagenesis

Conference Cancer Research · April 21, 2025 AbstractUndifferentiated pleomorphic sarcoma (UPS) is among the most common soft tissue sarcomas (STS) in adults. For decades, little therapeutic progress has been made for STSs, including UPSs. Targeted the ... Full text Cite

Abstract 2810: Investigating the oncogenic function of the long noncoding RNA KCNQ1OT1 in rhabdomyosarcoma

Conference Cancer Research · April 21, 2025 AbstractRhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and adolescents, with survival for high-risk cases stagnant at less than 30%. Contemporary molecular classification of RMS is ... Full text Cite

Abstract A025: Direct in vivo CRISPR screen identifies BAP1 and FAT1 as potent tumor suppressors in sarcomagenesis

Conference Cancer Research · March 11, 2025 AbstractUndifferentiated pleomorphic sarcoma (UPS) is among the most common soft tissue sarcomas (STS) in adults. For decades, little therapeutic progress has been made for STSs, including UPSs. Targeted the ... Full text Cite

Abstract 1092: RUNX2 inhibition alters PAX3::FOXO1 driven fusion-positive rhabdomyosarcoma cell state and growth

Conference Cancer Research · March 22, 2024 AbstractInvestigation: Fusion-positive rhabdomyosarcoma (FP-RMS) is an aggressive pediatric cancer of skeletal muscle lineage. While the incidence of RMS is ~4.5 patients per million individuals aged &lt ... Full text Cite

Abstract 5960: Targeting CDK8: A translatable therapeutic approach for fusion-positive aRMS

Conference Cancer Research · March 22, 2024 AbstractAlveolar rhabdomyosarcoma (aRMS), characterized by poor overall survival and limited advancements in therapy over the past four decades, poses a great challenge in childhood cancer treatment. More th ... Full text Cite

Abstract 3534: Interrogating the immune microenvironment of a novel mouse model of fusion positive rhabdomyosarcoma

Conference Cancer Research · April 4, 2023 AbstractImmunotherapies have been largely ineffective for pediatric soft tissue sarcomas, in particular for fusion-positive rhabdomyosarcoma (FP-RMS), characterized by the PAX-FOXO1 gene fusion. We are hampe ... Full text Cite

Abstract SY23-03: Rhabdomyosarcoma: New research tools for precision medicine

Conference Cancer Research · April 4, 2023 AbstractRhabdomyosarcoma (RMS) is a cancer of skeletal muscle histogenesis and the most common soft tissue sarcoma of childhood. Despite decades of basic and clinical research, survival for patients with hig ... Full text Cite

Abstract A08: Loss of noncanonical Hippo signaling in fusion-positive alveolar rhabdomyosarcoma increases invasiveness and a dedifferentiated phenotype associated with metastasis

Conference Molecular Cancer Research · August 1, 2020 AbstractA hallmark of alveolar rhabdomyosarcoma (ARMS) is the presence of a chromosomal translocation encoding the PAX3-FOXO1 fusion oncogene (FP-ARMS). Patients presenting with FP-ARMS represent the subset ... Full text Cite

Dysregulated Hippo signaling in childhood rhabdomyosarcoma.

Conference MOLECULAR CANCER RESEARCH · August 2020 Link to item Cite

Abstract A04: Genetic and pharmacologic inhibition of HES1 reduces YAP1 expression, impairing rhabdomyosarcoma cell growth

Conference Molecular Cancer Research · August 1, 2020 AbstractRhabdomyosarcoma (RMS) is a mesenchymal cancer with skeletal muscle histogenesis and the most common soft-tissue sarcoma of childhood. High-risk patient groups continue to have a poor survival (& ... Full text Cite

Abstract IA06: Dysregulated Hippo signaling in childhood rhabdomyosarcoma

Conference Molecular Cancer Research · August 1, 2020 AbstractRhabdomyosarcoma (RMS) is a mesenchymal cancer of skeletal muscle histogenesis and the most common soft tissue sarcoma of childhood. Survival for children with high-risk disease is less than 30% and ... Full text Cite

Abstract B15: Genomic classification and prognosis in rhabdomyosarcoma: A report from the Children’s Oncology Group, the Institute of Cancer Research, and the National Cancer Institute

Conference Cancer Research · July 15, 2020 AbstractPurpose: Rhabdomyosarcoma (RMS) is the most common soft-tissue sarcoma of childhood. Despite aggressive therapy, the 5-year survival rate for patients with metastatic or recurrent disease remains poo ... Full text Cite

Abstract 3670: Transcriptional co-activators TAZ/YAP are novel regulators of PAX3-FOXO1 transcriptional programing and fusion-positive rhabdomyosarcoma cancer cell stemness

Conference Cancer Research · July 1, 2019 AbstractIntroduction: Fusion Positive Rhabdomyosarcoma (FP-RMS), a soft tissue sarcoma of adolescents and young adults, is driven by the oncogenic transcription factor PAX3-FOXO1 (P3F). Although most pati ... Full text Cite

Abstract 5830: A novel Notch-YAP circuit drives stemness and tumorigenesis in embryonal rhabdomyosarcoma

Conference Cancer Research · July 1, 2017 AbstractIntroduction: Rhabdomyosarcoma (RMS), a tumor characterized by skeletal muscle features, is the most common soft tissue sarcoma in children and adolescents. The standard of care treatment has not cha ... Full text Cite

Abstract 4733: Notch signaling increases the number of relapse-driving tumor propagating cells in embryonal rhabdomyosarcoma

Conference Cancer Research · August 1, 2015 AbstractEmbryonal rhabdomyosarcoma (ERMS) is a devastating pediatric muscle cancer with extremely poor prognosis at relapse. Work from our group has identified the tumor-propagating cell (TPC) in a transgeni ... Full text Cite

Abstract A57: The secreted Wnt inhibitor SFRP3 is required for PAX3-FOXO1-positive alveolar rhabdomyosarcoma tumorigenesis

Conference Cancer Research · October 15, 2014 AbstractIntroduction: This study aims to understand the contribution of the Wnt pathway inhibitor secreted frizzled related protein 3 (SFRP3) to alveolar rhabdomyosarcoma tumorigenesis. Rhabdomyosarcoma is t ... Full text Cite

Abstract 481: In vivo imaging identifies that myf5+ embryonal rhabdomyosarcoma-propagating cells are dynamically reorganized during tumor growth

Conference Cancer Research · April 15, 2011 AbstractEmbryonal rhabdomyosarcoma (ERMS) is a devastating pediatric cancer with specific features of muscle differentiation. Here, we use a transgenic zebrafish model of RAS-induced ERMS and show that myf5+ ... Full text Cite